ClinicalTrials.gg
CompletedNCT07336940Updated Apr 1, 2026

Study of ENV-294 in Healthy Adults and in Adults With Moderate-to-Severe Atopic Dermatitis

A Phase 1 interventional study of ENV-294 Capsule in Atopic Dermatitis (AD), sponsored by Enveda Therapeutics. Completed at 5 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-01.

Sponsored by Enveda Therapeutics · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.

Enrollment
504th of 544
9 · median 96
Started
2025
with 40 others
Phase 1
82 of 639
10 open now
Registered
602nd of 639
by date

Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 504th largest by enrollment of the 544 interventional ones that give a count, is one of 41 that started in 2025, is one of 82 in phase 1, and was the 602nd registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:

73 more — sign in →

All 78 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 639 studies in Dermatitis, Atopic with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn about the safety and tolerability of ENV-294 in adults with moderate to severe atopic dermatitis. It may also learn about the changes ENV-294 may have on the severity of atopic dermatitis symptoms.

The main questions it will answer are:

  • Is ENV-294 safe and well tolerated in adults with moderate to severe atopic dermatitis?
  • Is there an impact on the severity of atopic dermatitis symptoms when participants take ENV-294? Researchers will review the atopic dermatitis present at the beginning of the study against the atopic dermatitis present at the end of the study.

Participants will:

  • Take drug ENV-294 once every day for 28 days
  • Visit the clinic weekly for 4 weeks for checkups and tests
  • Keep a diary of their symptoms and when they took their study drug ENV-294
03

Conditions studied

  • Atopic Dermatitis (AD)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be male or female participants who are 18 to 75 years of age
  • Have chronic AD (also known as atopic eczema) that was diagnosed at least 12 months prior to the first study visit
  • Have a history of inadequate response or intolerance to topical or other topical treatments for used atopic dermatitis
  • Have moderate-to-severe atopic dermatitis, at the first two study visits
  • Use an emollient (except those containing urea) daily for at least 1 week prior to the first study visit and throughout the study

Exclusion criteria

Exclusion Criteria:

  • Have any uncontrolled current or recurrent concomitant illness (eg, surface antigen, virus, or other condition) that could affect the study drug, clinical or laboratory assessments, or could impact participant safety.
  • Are using any medication (prescription or over-the-counter) that may interfere with the study product safety evaluations within 14-days prior to the second study visit.
  • Have the presence of any concomitant skin conditions (eg, psoriasis, seborrheic dermatitis) or have large tattoos that would interfere with clinical assessment, evaluation of AD, or treatment response.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Open-label with once per day dosing

    Drug: ENV-294 Capsule

Interventions

  • ENV-294 formulated as 200mg capsules for oral administration will be used for this study.

06

What researchers measure

Primary outcomes

  1. To assess the safety and tolerability of ENV-294 when administered to adult participants with moderate-to-severe atopic dermatitis.

    Incidence and severity of adverse events, serious adverse events and adverse events leading to the discontinuation of treatment.

    Time frame: From enrollment through treatment and the final study visit at approximately day 42.

  2. Incidence of abnormalities in clinical chemistry parameters as a measure of safety and tolerability of ENV-294.

    The number of participants with clinically significant abnormalities in clinical chemistry parameters will be assessed to evaluate safety and tolerability of multiple escalating doses of ENV-294.

    Time frame: Baseline through end of study at approximately Day 42.

  3. To assess the safety and tolerability of ENV-294 when administered to adult participants with moderate-to-severe atopic dermatitis

    Incidence of clinically significant changes in physical exam findings after ENV-294 administration.

    Time frame: From first dose through treatment and the final study visit at approximately day 42.

  4. Incidence of clinically significant changes in systolic blood pressure (mmHg) as a measure of safety and tolerability of ENV-294.

    The number of participants with clinically significant increases or decreases in systolic blood pressure, measured in millimeters of mercury (mmHg), will be assessed to evaluate the safety and tolerability of ENV-294 in adults with moderate-to-severe atopic dermatitis.

    Time frame: From first dose through treatment and the final study visit at approximately day 42.

  5. Incidence of clinically significant changes in heart rate (beats per minute) measured by 12-lead ECG as a measure of safety and tolerability of ENV-294.

    The number of participants with clinically significant changes in heart rate, measured in beats per minute from 12-lead ECG recordings, will be assessed to evaluate the cardiac safety and tolerability of ENV-294 in adults with moderate-to-severe atopic dermatitis.

    Time frame: Baseline through treatment and the final study visit at approximately day 42.

  6. Incidence of abnormalities in hematology parameters as a measure of safety and tolerability of ENV-294.

    The number of participants with clinically significant abnormalities in hematology parameters (e.g., hemoglobin, hematocrit, red blood cell count, white blood cell count, platelet count) will be assessed to evaluate safety and tolerability of multiple escalating doses of ENV-294.

    Time frame: Baseline through the end of the study at approximately Day 42.

  7. Incidence of abnormalities in coagulation parameters as a measure of safety and tolerability of ENV-294.

    The number of participants with clinically significant abnormalities in coagulation parameters (e.g., PT, aPTT, INR) will be assessed to evaluate safety and tolerability of multiple escalating doses of ENV-294.

    Time frame: Baseline through the end of the study at approximately Day 42.

  8. Incidence of abnormalities in urinalysis parameters as a measure of safety and tolerability of ENV-294.

    The number of participants with clinically significant abnormalities in urinalysis parameters (e.g., specific gravity, protein, glucose, blood, leukocytes) will be assessed to evaluate safety and tolerability of multiple escalating doses of ENV-294.

    Time frame: Baseline through the end of the study at approximately Day 42.

  9. Incidence of clinically significant changes in diastolic blood pressure (mmHg) as a measure of safety and tolerability of ENV-294.

    The number of participants with clinically significant increases or decreases in diastolic blood pressure, measured in millimeters of mercury (mmHg), will be assessed to evaluate the safety and tolerability of ENV-294 in adults with moderate-to-severe atopic dermatitis.

    Time frame: Baseline through treatment and the final study visit (approximately Day 42).

  10. Incidence of clinically significant changes in heart rate as a measure of safety and tolerability of ENV-294.

    The number of participants with clinically significant changes in heart rate (beats per minute) will be assessed to evaluate the safety and tolerability of ENV-294 in adults with moderate-to-severe atopic dermatitis.

    Time frame: Baseline through treatment and the final study visit (approximately Day 42).

  11. Incidence of clinically significant changes in respiratory rate as a measure of safety and tolerability of ENV-294.

    The number of participants with clinically significant changes in respiratory rate (breaths per minute) will be assessed to evaluate the safety and tolerability of ENV-294 in adults with moderate-to-severe atopic dermatitis

    Time frame: Baseline through treatment and the final study visit (approximately Day 42).

  12. Incidence of clinically significant changes in body temperature as a measure of safety and tolerability of ENV-294.

    The number of participants with clinically significant changes in body temperature (°C) will be assessed to evaluate the safety and tolerability of ENV-294 in adults with moderate-to-severe atopic dermatitis.

    Time frame: Baseline through treatment and the final study visit (approximately Day 42).

  13. Incidence of clinically significant changes in RR interval (milliseconds) measured by 12-lead ECG as a measure of safety and tolerability of ENV-294.

    The number of participants with clinically significant changes in RR interval, measured in milliseconds (ms) from 12-lead ECG recordings, will be assessed to evaluate the cardiac safety and tolerability of ENV-294.

    Time frame: Baseline through treatment and the final study visit (approximately Day 42).

  14. Incidence of clinically significant changes in PR interval (milliseconds) measured by 12-lead ECG as a measure of safety and tolerability of ENV-294.

    The number of participants with clinically significant changes in PR interval, measured in milliseconds (ms) from 12-lead ECG recordings, will be assessed to evaluate cardiac conduction safety of ENV-294.

    Time frame: Baseline through the end of the study at approximately Day 42.

  15. Incidence of clinically significant changes in QRS duration (milliseconds) measured by 12-lead ECG as a measure of safety and tolerability of ENV-294.

    The number of participants with clinically significant changes in QRS duration, measured in milliseconds (ms) from 12-lead ECG recordings, will be assessed to evaluate cardiac conduction safety of ENV-294.

    Time frame: Baseline through treatment and the final study visit (approximately Day 42).

  16. Incidence of clinically significant changes in QT interval (milliseconds) measured by 12-lead ECG as a measure of safety and tolerability of ENV-294.

    The number of participants with clinically significant changes in QT interval, measured in milliseconds (ms) from 12-lead ECG recordings, will be assessed to evaluate cardiac repolarization safety of ENV-294.

    Time frame: Baseline through treatment and the final study visit (approximately Day 42).

  17. Incidence of clinically significant changes in QTc Bazett (milliseconds) measured by 12-lead ECG as a measure of safety and tolerability of ENV-294.

    The number of participants with clinically significant changes in QTc Bazett (QT corrected for heart rate using Bazett's formula), measured in milliseconds (ms), will be assessed to evaluate cardiac safety of ENV-294.

    Time frame: Baseline through treatment and the final study visit (approximately Day 42)

  18. Incidence of clinically significant changes in QTc Fridericia (milliseconds) measured by 12-lead ECG as a measure of safety and tolerability of ENV-294.

    The number of participants with clinically significant changes in QTc Fridericia (QT corrected for heart rate using Fridericia's formula), measured in milliseconds (ms), will be assessed to evaluate cardiac safety of ENV-294.

    Time frame: From enrollment through treatment and the final study visit (approximately Day 42)

Secondary outcomes

  1. Maximum observed plasma concentration (Cmax) of ENV-294

    Maximum observed plasma concentration (Cmax) of ENV-294 will be determined from plasma samples collected at scheduled time points following oral administration to evaluate pharmacokinetic properties.

    Time frame: Pre and/or post-dose on days 1, 8, 15 and 28, and on day 42.

  2. Time to reach maximum plasma concentration (Tmax) of ENV-294

    Time to reach maximum observed plasma concentration (Tmax) of ENV-294 will be determined from plasma concentrations measured at scheduled post-dose time points.

    Time frame: Pre and/or post-dose on days 1, 8, 15 and 28, and on day 42.

  3. Area under the plasma concentration-time curve from time zero to 24 hours (AUC₀-₂₄h) of ENV-294

    Area under the plasma concentration-time curve from time zero to 24 hours (AUC₀-₂₄h) will be calculated from measured plasma concentrations of ENV-294 to assess systemic drug exposure after multiple oral doses.

    Time frame: Pre and/or post-dose on days 1, 8, 15 and 28, and on day 42.

07

Study locations

5 sites
  • Center for Dermatology Clinical Research, Inc.
    Fremont, California 94538, United States
  • Skin Sciences, PLLC
    Louisville, Kentucky 40217, United States
  • J & S Studies
    College Station, Texas 77845, United States
  • Texas Dermatology and Laser Specialists
    San Antonio, Texas 78218, United States
  • Virginia Dermatology & Skin Cancer Center
    Norfolk, Virginia 23502, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2025 to primary completion in Jan 2026, 4 months.

Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 4 months is below that.

Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2025
First posted
Jan 13, 2026
StartActual
Sep 10, 2025
Primary completionActual
Jan 13, 2026
CompletionActual
Jan 13, 2026
Last update
Apr 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07336940
Lead sponsor
Enveda Therapeutics
Responsible party
Sponsor
First posted
Jan 13, 2026
Start date
Sep 10, 2025
Primary completion
Jan 13, 2026
Completion
Jan 13, 2026
Last update
Apr 1, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ENV-294

Start the discussion